Desert Oasis Healthcare (DOHC) and Proteus Digital Health announced a multi-year collaboration established with a value-based contract. Enabled by Digital Medicines, this collaboration initiates a modern, “digital pathway” to improved medication adherence, demonstrated improvements in clinical outcomes, and reductions in hospital admissions for DOHC patients.
“We couldn’t be more excited to finally have a proven, FDA approved way to know when patients take their medications,” said Brian Hodgkins Pharm.D., Executive Vice President of Desert Oasis Healthcare. “It’s known that more than 50% of patients do not take their medications as prescribed. Now DOHC, like other healthcare providers, can use data from Digital Medicines to help patients get the real value out of their prescriptions and meet their health goals.”
Proteus has a panel of more than 20 Digital Medicines that treat cardiovascular and metabolic diseases including hypertension and diabetes being prescribed to patients in the United States. They are prepared and delivered via specialty pharmacy services.
Through a value-based contract, Desert Oasis Healthcare joins a select group of health systems in the U.S. who use Digital Medicines to focus on improving outcomes in high-risk patients. Proteus has conducted several clinical studies demonstrating the clinical and economic benefits of using Digital Medicines to improve outcomes in these patients, including a successful randomized control trial in patients with uncontrolled hypertension and type 2 diabetes (J Med Internet Res 2017;19(7):e246).
“The value-based contract with Desert Oasis Healthcare means they reduce hospital admissions for their patients through greater health outcomes based on measured high levels of adherence to key cardiovascular and metabolic Digital Medicines, as well as control of blood pressure and hemoglobin A1c,” said Joe McKenna, Proteus Vice President of Customer Partnering. “The patient stays healthier and DOHC contains its costs through fewer hospital admissions.”